Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

Abstract

Background Galectin‐3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non‐small cell lung cancer (NSCLC). However, the prognostic impact of GAL3 expression on patients with resected NSCLC receiving platinum‐based adjuvant chemotherapy (AC) remains unclear. This study aimed to determine the prognostic significance of GAL3 expression in NSCLC patients receiving platinum‐based AC. Methods The study included 111 patients with completely resected stages II and IIIA NSCLC who were receiving platinum‐based AC. GAL3 expression in cancer cells was evaluated immunohistochemically according to H‐score (“histo score), with a score of ≥170 considered as high expression. The correlation of GAL3 expression with clinicopathological characteristics and survival was subsequently evaluated. Results In survival analysis, GAL3 expression was significantly associated with recurrence‐free survival (RFS) and overall survival (OS). In multivariate analysis, GAL3 expression was an independent predictive factor of RFS rather than OS. Conclusions GAL3 expression is a reliable biomarker to predict the prognosis of completely resected NSCLC patients receiving platinum‐based AC.

Soluble galectin‐3 as a microenvironment‐relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

“…In consequence, our results revealed that the secretion of sGAL‐3 on resected LUAD patients' plasma (in a validation set) is an independent prognostic biomarker for RFS and OS. In accordance with our results, previous studies in early NSCLC reported that GAL‐3 expression on tumor cells has been reported to be associated with progression, poor prognosis and recurrence after radical resection on tissue samples [ 61 ]. Using non‐invasive methodologies, Yoko Kataoka et al.…”

N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer

“… 46 This method was used to evaluate the semi-quantitative expression of target proteins using the following formula: immunoreactivity score = staining intensity score (0: no staining, 1: weak, 2: moderate, and 3: strong staining) × proportion of positive cells score. 47 The expression level of target proteins was considered “low expression” if the H-score was 0–4 and “high expression” if the score was 5–9.…”

Galectins in epithelial-mesenchymal transition: roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis

“…Gal-3 overexpression has been associated with poor prognosis and lower patient survival rates in different types of cancer [ 150 , 173 – 178 ].…”